Pharma Running Up Against Deadline for Assessing Excipient Risks
This article was originally published in The Gold Sheet
Executive Summary
Pharmaceutical manufacturers may not have enough time to comply with the EU’s new risk assessment guideline, which goes into effect early next year. The magnitude of the task involved in evaluating excipient risk poses a challenge for the pharmaceutical industry and excipient makers alike.